← Leaderboards
Curtis Donskey
Louis Stokes Cleveland Va Medical Center
$2,349,865
Attributed
$2,349,865
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $450.5K · FY2008–23$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
AHRQ$1,328,662 · 1
CDC$1,021,203 · 1
VA$0 · 4
By mechanism
R18$1,328,662 · 1
R01$1,021,203 · 1
I01$0 · 4
Top collaborators
- Krisztina Margaret Papp-Wallace1 shared
Most similar at Louis Stokes Cleveland Va Medical Center
Same institution · by research overlap
- Robert A. Bonomo$11,448,603
- Krisztina Margaret Papp-Wallace$0
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionHealthcare SystemsTransmission ProcessLaboratoriesReproduction SporesClostridium DifficileMorbidity - Disease RateCostRandomized TrialAntibiotic TherapyMortalityResearch PersonnelSuccessCommunitiesRecoveryComplicationNursing HomesCollaborationsHospitalsPathogenMedicalBacteroidesEffective TherapyBacteria
Grant awards (19)
Targeting Burkholderial β-lactamases: Structure, function, and regulation$0
I01 · FY2023 · VA · contact PI
Microbiologic impact of medical therapies for recurrent Clostridium difficile infection$0
I01 · FY2023 · VA · contact PI
Microbiologic impact of medical therapies for recurrent Clostridium difficile infection$0
I01 · FY2022 · VA · contact PI
Microbiologic impact of medical therapies for recurrent Clostridium difficile infection$0
I01 · FY2021 · VA · contact PI
Microbiologic impact of medical therapies for recurrent Clostridium difficile infection$0
I01 · FY2021 · VA · contact PI
Microbiologic impact of medical therapies for recurrent Clostridium difficile infection$0
I01 · FY2019 · VA · contact PI
Unlocking the sporicidal potential of alcohol against Clostridium difficile$0
I01 · FY2018 · VA · contact PI
Unlocking the sporicidal potential of alcohol against Clostridium difficile$0
I01 · FY2017 · VA · contact PI
Unlocking the sporicidal potential of alcohol against Clostridium difficile$0
I01 · FY2016 · VA · contact PI
An environmental disinfection intervention to prevent C. difficile transmission$0
I01 · FY2014 · VA · contact PI
An environmental disinfection intervention to control Clostridium difficile$450,478
R18 · FY2013 · HS · contact PI
An environmental disinfection intervention to prevent C. difficile transmission$0
I01 · FY2013 · VA · contact PI
An environmental disinfection intervention to control Clostridium difficile$433,340
R18 · FY2012 · HS · contact PI
An environmental disinfection intervention to prevent C. difficile transmission$0
I01 · FY2012 · VA · contact PI
An environmental disinfection intervention to control Clostridium difficile$444,844
R18 · FY2011 · HS · contact PI
An environmental disinfection intervention to prevent C. difficile transmission$0
I01 · FY2011 · VA · contact PI
Development, Implementation and Evaluation of Novel Strategies to Reduce Inapprop$346,500
R01 · FY2010 · CI · contact PI
Development, Implementation and Evaluation of Novel Strategies to Reduce Inapprop$341,703
R01 · FY2009 · CI · contact PI
Development, Implementation and Evaluation of Novel Strategies to Reduce Inapprop$333,000
R01 · FY2008 · CI · contact PI